Management discusses the preliminary data to be presented as posters at ESMO-IO on a conference call to be held on December 7 at 8:30 am. Webcast Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CGEN:
- Compugen’s COM701 shows durable anti-tumor activity in ovarian cancer
- Compugen’s COM701 shows preliminary anti-tumor activity in ovarian cancer
- Compugen management to meet virtually with Oppenheimer
- Compugen price target lowered to $8 from $12 at Oppenheimer
- Compugen Reports Third Quarter 2022 Results